|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,070 GBX | -4.46% |
|
+3.38% | +57.35% |
| Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
| Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
4basebio PLC reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was GBP 0.268 million compared to GBP 0.338 million a year ago. Net loss was GBP 5.15 million compared to GBP 3.24 million a year ago.
Basic loss per share from continuing operations was GBP 0.42 compared to GBP 0.26 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +57.35% | 171M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
4BASEBIO PLC 
